Related Experiment Video
Updated: Dec 9, 2025

12:36
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
Published on: March 14, 2020
17.2K
Changed Profile of Serum Transferrin Isoforms in Primary Biliary Cholangitis
Agnieszka Grytczuk1, Alicja Bauer2, Ewa Gruszewska3
1Department of Laboratory Diagnostics, University Clinical Hospital, 15-540 Bialystok, Poland.
Journal of Clinical Medicine
|September 11, 2020
Summary
Serum transferrin isoforms are altered in primary biliary cholangitis (PBC), a cholestatic liver disease. Lower levels of specific transferrin isoforms were observed in PBC patients compared to healthy individuals.
Area of Science:
- Biochemistry
- Hepatology
- Clinical Chemistry
Background:
- Liver damage in cholestatic diseases like primary biliary cholangitis (PBC) alters protein synthesis and posttranslational modifications, including glycosylation.
- Hydrophobic bile acid retention is a key factor in liver damage associated with PBC.
Purpose of the Study:
- To investigate the serum transferrin isoform profile in patients with primary biliary cholangitis (PBC).
- To compare the transferrin isoform profile in PBC with that observed in extrahepatic cholestasis.
Main Methods:
- Analysis of transferrin isoforms using capillary electrophoresis.
- Study involved 76 patients with PBC and 40 healthy blood donors.
Main Results:
- Significantly lower mean relative concentrations of disialotransferrin and trisialotransferrin were found in PBC patients compared to healthy subjects.
- No correlation was observed between transferrin isoform levels and histological disease severity (Ludwig scoring system).
- Disease stage correlated with alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) activity, and albumin levels.
Conclusions:
- The serum transferrin isoform profile is altered in primary biliary cholangitis (PBC) and differs from that in extrahepatic cholestasis.
- Decreased concentrations of lower sialylated transferrin isoforms in PBC are not linked to the histological stage of the disease.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
127
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
127
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
102
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
102

